Related Experiment Videos
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells
1Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Abstract:
DNA protein cross-links (DPC), DNA interstrand cross-links (ISCL), and DNA single strand breaks following treatment of experimental ovarian tumor cells (O-342) with five new metal complexes (three platinum, one titanium, one ruthenium compounds) were investigated at 6, 24, and 48 h after drug exposure and compared with their in vitro growth inhibitory potential. cis-Diamminedichloroplatinum(II) (cisplatin, DDP) served as reference drug. The following new compounds were tested: 18-crown-6-tetracarboxybis-diammineplatinum(II) (CTDP), cis-aminotrismethylenephosphonato-diammineplatinum(II) (AMDP), cis-diamminecyclohexano-aminotrismethylenephosphonato-platin um(II) (DAMP), diethoxybis-(1-phenylbutane-1,3-dionato)-titanium(IV) (budotitane), and trans-indazolium-tetrachlorobisindazole-ruthenate(III) (IndCR). At equimolar concentrations DNA cross-linking activity of the platinum agents decreased in the order cisplatin, CTDP, AMDP, DAMP; this was paralleled by growth inhibition in a cell proliferation assay. CTDP-induced interstrand cross-linking occurred more slowly compared to cisplatin (DDP) (6 h: CTDP, 73 +/- 15 versus DDP, 365 +/- 72 rad equivalents), but reached a peak similar to cisplatin 24 h after exposure (CTDP, 317 +/- 68 versus DDP, 392 +/- 116 rad equivalents). At this time point in contrast to DDP no DNA protein cross-links were observed for CTDP (total cross-links: CTDP 310 +/- 71, DDP 1987 +/- 436 rad equivalents). Thus, at 24 h, CTDP was found to be distinctly less reactive to proteins than DDP, and it is suggested that CTDP might be similar in its toxicity pattern to the structurally related compound carboplatin which was also reported to be less reactive to protein than DDP. By 48 h, CTDP- and DDP-induced interstrand cross-links were 65 +/- 21 and 180 +/- 33 rad equivalents, respectively. Although at a lower level, by 24 h, AMDP showed a ratio of ISCL to total cross-links (179 +/- 39 versus 213 +/- 31 rad equivalents), which was comparable to CTDP. The second biphosphonate complex DAMP was the least active platinum compound in terms of DNA damage, effecting only 16 +/- 7 rad equivalents ISCL and 63 +/- 28 rad equivalents total cross-links; similar to DDP, DAMP displayed a higher DPC fraction at 24 h. The titanium complex diethoxybis-(1-phenylbutane-1,3-dionato)-tita-++ +nium(IV) showed dose-dependent inhibition of cell proliferation, while no significant DNA damage could be detected with the alkaline elution technique. These results, together with observations from other authors, indicating that space-filling planar aromatic ring systems are important for its antitumor activity, suggest as possible mechanism of action of diethoxybis-(1-phenylbutane-1,3-dionato)-titanium(IV) intercalation into the DNA.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
New platinum complexes show varying DNA damage and growth inhibition in ovarian tumor cells. One platinum compound, CTDP, exhibits less protein reactivity, similar to carboplatin, suggesting a potentially different toxicity profile.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Metal complexes are investigated for their anticancer properties.
- DNA damage, including cross-links and strand breaks, is a key mechanism of action for many chemotherapeutics.
- Platinum-based drugs are widely used in cancer treatment, but their reactivity with proteins can influence toxicity.
Purpose of the Study:
- To evaluate the DNA cross-linking activity (DNA protein cross-links and DNA interstrand cross-links) and in vitro growth inhibitory potential of new platinum, titanium, and ruthenium complexes.
- To compare the DNA damage profiles and cytotoxicity of these novel compounds with cisplatin (DDP).
- To explore potential mechanisms of action for the titanium complex.
Main Methods:
- Treatment of experimental ovarian tumor cells (O-342) with five metal complexes (three platinum, one titanium, one ruthenium).
- Assessment of DNA protein cross-links (DPC) and DNA interstrand cross-links (ISCL) using alkaline elution at 6, 24, and 48 hours post-treatment.
- Evaluation of in vitro growth inhibition using a cell proliferation assay.
- Comparison with cisplatin (DDP) as a reference drug.
Main Results:
- DNA cross-linking activity of platinum agents decreased in the order: cisplatin, CTDP, AMDP, DAMP, paralleled by growth inhibition.
- CTDP induced ISCL more slowly than DDP but reached a similar peak at 24 hours; notably, CTDP showed no DPC at 24 hours, unlike DDP.
- The titanium complex (budotitane) inhibited cell proliferation dose-dependently, but no significant DNA damage was detected, suggesting potential DNA intercalation as a mechanism.
Conclusions:
- The platinum complex CTDP exhibits a distinct DNA damage and protein reactivity profile compared to DDP, potentially similar to carboplatin.
- AMDP showed a comparable ratio of ISCL to total cross-links as CTDP at 24 hours.
- DAMP was the least active platinum compound, with a higher DPC fraction similar to DDP.
- The titanium complex's mechanism of action may involve DNA intercalation.